Folgen
Jakob Michael Riedl
Jakob Michael Riedl
Bestätigte E-Mail-Adresse bei medunigraz.at
Titel
Zitiert von
Zitiert von
Jahr
Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer
F Posch, K Silina, S Leibl, A Mündlein, H Moch, A Siebenhüner, ...
Oncoimmunology 7 (2), e1378844, 2018
2222018
The width of resection margins influences local recurrence in soft tissue sarcoma patients
V Kainhofer, MA Smolle, J Szkandera, B Liegl-Atzwanger, W Maurer-Ertl, ...
European Journal of Surgical Oncology (EJSO) 42 (6), 899-906, 2016
972016
C-reactive protein (CRP) levels in immune checkpoint inhibitor response and progression in advanced non-small cell lung cancer: a bi-center study
JM Riedl, DA Barth, WM Brueckl, G Zeitler, V Foris, S Mollnar, M Stotz, ...
Cancers 12 (8), 2319, 2020
622020
The AST/ALT (De Ritis) ratio predicts clinical outcome in patients with pancreatic cancer treated with first-line nab-paclitaxel and gemcitabine: post hoc analysis of …
JM Riedl, F Posch, G Prager, W Eisterer, L Oehler, T Sliwa, K Wilthoner, ...
Therapeutic advances in medical oncology 12, 1758835919900872, 2020
452020
Gemcitabine/nab-Paclitaxel versus FOLFIRINOX for palliative first-line treatment of advanced pancreatic cancer: A propensity score analysis
JM Riedl, F Posch, L Horvath, A Gantschnigg, F Renneberg, ...
European Journal of Cancer 151, 3-13, 2021
362021
Inflammatory biomarkers in metastatic colorectal cancer: prognostic and predictive role beyond the first line setting
JM Riedl, F Posch, F Moik, A Bezan, J Szkandera, MA Smolle, ...
Oncotarget 8 (56), 96048, 2017
332017
Comparison of three commercial decision support platforms for matching of next-generation sequencing results with therapies in patients with cancer
SO Perakis, S Weber, Q Zhou, R Graf, S Hojas, JM Riedl, A Gerger, ...
Esmo Open 5 (5), e000872, 2020
292020
Cell-free DNA analysis reveals POLR1D-mediated resistance to bevacizumab in colorectal cancer
Q Zhou, SO Perakis, P Ulz, S Mohan, JM Riedl, E Talakic, S Lax, M Tötsch, ...
Genome Medicine 12, 1-17, 2020
272020
Benefit of second-line systemic chemotherapy for advanced biliary tract cancer: A propensity score analysis
F Moik, JM Riedl, T Winder, A Terbuch, CH Rossmann, J Szkandera, ...
Scientific Reports 9 (1), 5548, 2019
222019
Cancer stem cell gene variants in CD44 predict outcome in stage II and stage III colon cancer patients
M Stotz, SA Herzog, M Pichler, M Smolle, J Riedl, C Rossmann, A Bezan, ...
Anticancer Research 37 (4), 2011-2018, 2017
212017
External validation of the prognostic relevance of the advanced lung cancer inflammation index (ALI) in pancreatic cancer patients
DA Barth, C Brenner, JM Riedl, F Prinz, EV Klocker, K Schlick, P Kornprat, ...
Cancer Medicine 9 (15), 5473-5479, 2020
192020
Maturation of tertiary lymphoid structures and recurrence of stage II and III colorectal cancer. Oncoimmunology 7, e1378844
F Posch, K Silina, S Leibl, A Mündlein, H Moch, A Siebenhüner, ...
192018
The AST/ALT ratio is an independent prognostic marker for disease-free survival in stage II and III colorectal carcinoma
L Scheipner, MA Smolle, D Barth, F Posch, M Stotz, M Pichler, H Stoeger, ...
Anticancer Research 41 (1), 429-436, 2021
182021
Surgery for metachronous metastasis of soft tissue sarcoma–A magnitude of benefit analysis using propensity score methods
MA Smolle, VM van Praag, F Posch, M Bergovec, L Leitner, ...
European Journal of Surgical Oncology 45 (2), 242-248, 2019
172019
Microvascular density assessed by CD31 predicts clinical benefit upon bevacizumab treatment in metastatic colorectal cancer: results of the PassionATE study, a translational …
D Bianconi, M Herac, F Posch, M Schmeidl, M Unseld, M Kieler, ...
Therapeutic Advances in Medical Oncology 12, 1758835920928635, 2020
162020
Individualizing follow-up strategies in high-grade soft tissue sarcoma with flexible parametric competing risk regression models
MA Smolle, M van de Sande, D Callegaro, J Wunder, A Hayes, L Leitner, ...
Cancers 12 (1), 47, 2019
162019
Patterns of venous thromboembolism risk in patients with localized colorectal cancer undergoing adjuvant chemotherapy or active surveillance: an observational cohort study
JM Riedl, F Posch, A Bezan, J Szkandera, MA Smolle, T Winder, ...
BMC cancer 17, 1-8, 2017
152017
T-regulatory cells predict clinical outcome in soft tissue sarcoma patients: A clinico-pathological study
MA Smolle, L Herbsthofer, B Granegger, M Goda, I Brcic, M Bergovec, ...
British journal of cancer 125 (5), 717-724, 2021
142021
The lipase/amylase ratio (LAR) in peripheral blood might represent a novel prognostic marker in patients with surgically resectable pancreatic cancer
M Stotz, DA Barth, JM Riedl, E Asamer, EV Klocker, P Kornprat, ...
Cancers 12 (7), 1798, 2020
112020
Decreased activity of circulating butyrylcholinesterase in blood is an independent prognostic marker in pancreatic cancer patients
EV Klocker, DA Barth, JM Riedl, F Prinz, J Szkandera, K Schlick, ...
Cancers 12 (5), 1154, 2020
112020
Das System kann den Vorgang jetzt nicht ausführen. Versuchen Sie es später erneut.
Artikel 1–20